Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Earnings for Nektar Therapeutics (NKTR)
Earnings in 2023 (TTM): $-276,256,000
According to Nektar Therapeutics's latest financial reports the company's current earnings (TTM) are $-276,256,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Nektar Therapeutics
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-276,256,000 | $-276,056,000 |
| 2022 | $-364,983,000 | $-368,198,000 |
| 2021 | $-523,280,000 | $-523,837,000 |
| 2020 | $-443,947,000 | $-444,440,000 |
| 2019 | $-440,054,000 | $-440,667,000 |
| 2018 | $682.73 M | $681.31 M |
| 2017 | $-96,076,000 | $-96,692,000 |
| 2016 | $-152,648,000 | $-153,524,000 |
| 2015 | $-80,671,000 | $-81,177,000 |
| 2014 | $-54,428,000 | $-53,916,000 |
| 2013 | $-159,768,000 | $-162,013,000 |
| 2012 | $-171,449,000 | $-171,855,000 |
| 2011 | $-132,960,000 | $-133,978,000 |
| 2010 | $-37,057,000 | $-37,938,000 |
| 2009 | $-102,772,000 | $-102,519,000 |
| 2008 | $35.14 M | $-34,336,000 |
| 2007 | $-31,452,000 | $-32,761,000 |
| 2006 | $-153,933,000 | $-154,761,000 |
| 2005 | $-185,248,000 | $-185,111,000 |
| 2004 | $-102,049,000 | $-101,886,000 |
| 2003 | $-46,513,000 | $-46,682,000 |
| 2002 | $-107,468,000 | $-107,468,000 |
| 2001 | $-250,008,000 | $-250,008,000 |
| 2000 | $-97,403,000 | $-97,403,000 |
| 1999 | $-50,374,000 | $-38,448,000 |
| 1998 | $ | $-18,356,000 |
| 1997 | $ | $-9,983,000 |
| 1996 | $-9,900,000 | $-10,000,000 |
| 1995 | $-7,500,000 | $-7,700,000 |
| 1994 | $-5,100,000 | $-5,300,000 |